Stock A115450 HLB THERAPEUTICS CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials HLB Therapeutics Co.,Ltd.

Equities

A115450

KR7115450009

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 09/05/2024 BST 		5-day change 1st Jan Change
9,340 KRW -5.56% Intraday chart for HLB Therapeutics Co.,Ltd. -11.89% +113.00%
04-01 HLB Therapeutics Co.,Ltd. announced that it has received KRW 29.99999658 billion in funding from HLB Co., Ltd. CI
03-18 HLB Therapeutics Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 681,938 773,154 776,711 378,914 365,136 331,362
Enterprise Value (EV) 1 673,937 773,776 761,260 329,473 353,255 309,032
P/E ratio 144 x -45.8 x -43.9 x -22.4 x -30.6 x -136 x
Yield - - - - - -
Capitalization / Revenue 14.7 x 13.1 x 18.1 x 8.69 x 7.59 x 6.16 x
EV / Revenue 14.5 x 13.1 x 17.7 x 7.56 x 7.34 x 5.75 x
EV / EBITDA -261 x -69.1 x -72 x -35.1 x -56.9 x -851 x
EV / FCF -99.7 x -57.5 x -42.1 x -26 x -23.9 x 42.4 x
FCF Yield -1% -1.74% -2.38% -3.84% -4.19% 2.36%
Price to Book 9.93 x 12.1 x 8.71 x 3.7 x 3.04 x 2.01 x
Nbr of stocks (in thousands) 51,809 52,922 56,989 57,371 67,485 75,567
Reference price 2 13,163 14,609 13,629 6,605 5,411 4,385
Announcement Date 21/03/19 19/03/20 17/03/21 18/03/22 20/03/23 18/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 46,357 58,966 42,930 43,586 48,132 53,749
EBITDA 1 -2,585 -11,194 -10,566 -9,386 -6,211 -363.1
EBIT 1 -3,057 -11,883 -11,267 -11,087 -7,877 -8,842
Operating Margin -6.6% -20.15% -26.24% -25.44% -16.37% -16.45%
Earnings before Tax (EBT) 1 3,998 -16,732 -17,401 -17,764 -12,104 -2,769
Net income 1 4,575 -16,423 -16,902 -17,197 -11,354 -2,302
Net margin 9.87% -27.85% -39.37% -39.46% -23.59% -4.28%
EPS 2 91.40 -318.9 -310.1 -294.2 -176.6 -32.13
Free Cash Flow 1 -6,758 -13,464 -18,101 -12,654 -14,800 7,288
FCF margin -14.58% -22.83% -42.16% -29.03% -30.75% 13.56%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 21/03/19 19/03/20 17/03/21 18/03/22 20/03/23 18/03/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 622 - - - -
Net Cash position 1 8,001 - 15,451 49,441 11,881 22,330
Leverage (Debt/EBITDA) - -0.0555 x - - - -
Free Cash Flow 1 -6,758 -13,464 -18,101 -12,654 -14,800 7,288
ROE (net income / shareholders' equity) 6.69% -21.2% -19.7% -15.4% -9.38% -1.85%
ROA (Net income/ Total Assets) -2.24% -6.01% -5.39% -4.45% -2.61% -2.85%
Assets 1 -203,935 273,300 313,798 386,732 435,124 80,905
Book Value Per Share 2 1,325 1,208 1,566 1,785 1,780 2,177
Cash Flow per Share 2 321.0 816.0 244.0 1,503 699.0 322.0
Capex 1 223 556 85.5 823 3,396 302
Capex / Sales 0.48% 0.94% 0.2% 1.89% 7.06% 0.56%
Announcement Date 21/03/19 19/03/20 17/03/21 18/03/22 20/03/23 18/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
HLB THERAPEUTICS CO.,LTD. Stock HLB Therapeutics Co.,Ltd.
+113.00% 570M
MCKESSON CORPORATION Stock McKesson Corporation
+20.94% 72.16B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
-1.26% 23.88B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+8.25% 8.35B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+5.13% 8.29B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-19.42% 8.18B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+5.56% 4.81B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+16.83% 4.4B
EBOS GROUP LIMITED Stock EBOS Group Limited
-1.83% 4B
GALENICA AG Stock Galenica AG
-1.65% 3.92B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. A115450 Stock
  4. Financials HLB Therapeutics Co.,Ltd.